Organovo (Nyse: ONVO) reported $50 million in cash reserves and plans to use the funds to ramp up research and development efforts. CEO Keith Murphy said in an earnings call that the company is on track to release its first product — a drug toxicity test that uses liver tissues synthesized by Organovo’s 3-D bioprinters — commercially next year.

The company began the year trading at $2.36, and has since more than tripled closing at $9.36 on Nov. 12. It also upgraded from the over-the-counter markets to the New York Stock Exchange in July and completed a $46.6 million public offering in August.